Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
DBV Technologies SA (DBVT) is a clinical-stage biopharmaceutical leader advancing epicutaneous immunotherapy (EPIT) through its innovative Viaskin platform, targeting food allergies with non-invasive precision. This page aggregates all essential updates on the company’s clinical progress, regulatory milestones, and strategic initiatives.
Investors and stakeholders gain centralized access to critical developments including phase trial results, FDA/EMA interactions, and partnership announcements. Each update is curated to provide actionable insights into DBVT’s pioneering work in allergy treatment while maintaining rigorous scientific accuracy.
Key coverage areas include Viaskin efficacy data, patent developments, and manufacturing scalability updates. The resource is designed to help users track the company’s progress from clinical research to potential commercialization without requiring cross-platform monitoring.
Bookmark this page for streamlined tracking of DBV Technologies’ advancements in redefining food allergy management through its unique skin-based immunotherapy approach.
DBV Technologies (DBVT) has released its monthly voting rights disclosure for April 30, 2025. The company reported a total of 136,948,872 shares outstanding. The gross voting rights stand at 136,948,872, while the net voting rights amount to 136,762,549. This disclosure is made in compliance with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers (AMF) for companies listed on NYSE Euronext Paris.
DBV Technologies (DBVT) has announced that its Chief Executive Officer, Daniel Tassé, will participate in a fireside chat at the Citizens JMP Life Sciences Conference. The event is scheduled for Wednesday, May 7, 2025, at 11:00am ET in New York, NY. Investors and interested parties can access a live webcast of the presentation through the company's website, and a replay will be available for 90 days following the event.
DBV Technologies reported its Q1 2025 financial results, showing a decrease in cash position to $13.0 million as of March 31, 2025, down from $32.5 million at the end of 2024. The company's net loss was $27.1 million, or $(0.26) per share, slightly improved from $27.3 million in Q1 2024.
Key financial highlights include:
- Operating expenses decreased to $27.4 million from $30.0 million year-over-year
- Research & Development costs remained stable at $21.5 million
- Operating income declined to $0.8 million from $1.4 million
Notably, the company secured a significant financing of up to $306.9 million on March 27, 2025, with initial proceeds of $125.5 million received in April 2025. This funding is intended to advance the Viaskin Peanut Patch through BLA submission and potential U.S. commercial launch. The company projects its current cash position will fund operations into June 2026.
DBV Technologies (DBVT) has announced the filing of its 2024 Annual Report on Form 10-K with the SEC and Universal Registration Document (URD) with the French AMF. The company's audited financial statements for the year ended December 31, 2024, were approved by the Board of Directors on April 11, 2025, showing no changes from the unaudited statements published on March 24, 2025.
The 2024 URD includes the Annual Financial Report, Management Report, Corporate Governance Report, and Share Buyback Program description. Both documents are accessible through the company's website, with the URD available on AMF's website and Form 10-K on SEC's website. Free printed copies can be obtained at DBV's headquarters in Châtillon, France.
DBV Technologies (DBVT) has secured a financing package of up to $306.9 million to advance its Viaskin® peanut patch program. The funding includes $125.5 million upfront and potential additional $181.4 million from warrant exercises.
The financing will support the company through its expected Biologics License Application (BLA) submission to FDA for the Viaskin® peanut patch in children aged 4-7 years and potential commercial launch. The VITESSE Phase 3 study has enrolled 654 subjects, exceeding the target of 600, with results expected in Q4 2025.
Key investors include MPM BioImpact, Adage Capital Management, Janus Henderson Investors, and others. The financing will result in an immediate dilution of 22.4% and potential maximum dilution of 73.7% if all warrants are exercised. The funding extends DBV's financial visibility into 2028, supporting potential US commercialization if approved.
FAQ
What is the current stock price of Dbv Technologies S A (DBVT)?
What is the market cap of Dbv Technologies S A (DBVT)?
